ReviewAnnals of medicine and surgery (2012)2026
Perioperative management of vasoplegic syndrome in cardiac surgery: a narrative review.
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoplegic syndrome (VS) is a frequent and potentially life-threatening complication following cardiac surgery with cardiopulmonary bypass (CPB) and is associated with significant morbidity and mortality. It is characterized by persistent hypotension, low systemic vascular resistance, and preserved or elevated cardiac output despite adequate volume resuscitation. This narrative review provides a comprehensive and clinically focused synthesis of current evidence on the pathophysiology, risk factors, diagnosis, and perioperative management of VS. A structured literature search of the PubMed database was conducted, focusing on studies published from 2020 to 2026 and complemented by key landmark trials. The pathophysiology of VS is multifactorial, involving systemic inflammatory activation, excessive nitric oxide production, vasopressin depletion, dysregulation of the renin-angiotensin-aldosterone system, and impaired vascular responsiveness to catecholamines. Major risk factors include preoperative use of ACE inhibitors or angiotensin receptor blockers, impaired cardiac function, prolonged CPB duration, and complex surgical procedures. Early recognition and differentiation from other causes of perioperative shock are essential for timely management. Current therapeutic strategies emphasize a multimodal, physiology-guided approach combining catecholamines with non-adrenergic agents such as vasopressin, methylene blue, hydroxocobalamin, and angiotensin II, particularly in refractory cases. Emerging evidence supports early combination vasopressor strategies to improve hemodynamic stability and reduce catecholamine exposure. However, optimal treatment sequencing and patient selection remain uncertain. A structured, algorithm-based approach integrating early diagnosis, targeted therapies, and advanced hemodynamic monitoring may improve clinical outcomes. Further research is needed to refine diagnostic criteria, identify reliable biomarkers, and establish evidence-based management algorithms for VS in cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.